Treatment of chronic hepatitis C: A systematic review

Hepatology

Volumn 36, Issue 5, 2002, Pages S135-S144

  Chander, Geetanjali ^a   Sulkowski, Mark S ^a   Jenckes, Mollie W ^a   Torbenson, Michael S ^a   Herlong, H Franklin ^a   Bass, Eric B ^a,b   Gebo, Kelly A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 0036829986     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.37146     Document Type: Article

References (62)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao FX, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
3. Gretch DR, dela Rosa C, Carithers RL Jr, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications. Ann Intern Med 1995;123:321-329.
4. Weiss JB Jr, Persing DH. Hepatitis C: Advances in diagnosis. Mayo Clin Proc 1995;70:296-297.
5. Davis GL, Lau JY, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994;23:603-613.
6. Management of hepatitis C. NIH Consensus Statement. 1997 March 24-26;15(3):1-41.
7. Gebo K, Jenckes M, Chander G, et al. Management of Chronic Hepatitis C. Evidence Report/Technology Assessment No. 60 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No 290-97-0006). AHRQ Publication No. 02-E030. Rockville, MD: Agency for Healthcare Research and Quality. July 2002.
8. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-240.
9. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001;285:193-199.
10. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. BMJ 2001;323:1151-1155.
11. McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, Robinson KA, et al. Management of New Onset Atrial Fibrillation No. 12 (prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-097-0006). AHRQ Publication No. 01-E026. Rockville, MD: Agency for Healthcare Quality and Research, 2001.
12. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT, et al. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 1999;281:1318-1325.
13. Mangia A, Villani MR, Minerva N, Leandro G, Bacca D, Cela M, Carretta V, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: A randomized controlled trial. J Hepatol 2001;34:441-446.
14. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34:1006-1011.
15. Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: A randomized multicenter trial. Liver 2000;20:427-436.
16. el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999;31:472-475.
17. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
18. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438.
19. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
20. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
21. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-653.
22. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
23. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F Jr, Daeussinger D, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled multicenter study. Gastroenterology 2001;120:A289.
24. Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000;95:2928-2935.
25. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, Barbarini G. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol 1999;34:928-933.
26. Bresci G, Parisi G, Bertoni M, Capria A. High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon. Dig Liver Dis 2000;32:703-707.
27. Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Muller C, et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: Final results of a prospective randomized trial. Eur J Gastroenterol Hepatol 2001a;13:699-705.
28. Tripi S, DiGaetano G, Sotesi M, Cartabellotta F, Vassallo R, Carroccio A, Anastasi G, et al. Interferon-alpha alone versus interferon-alpha plus ribavirin in patients with chronic hepatitis C not responding to previous interferon-alpha treatment. Biodrugs 2000;13:299-304.
29. Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001;34:133-138.
30. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon. Hepatology 2001;33:704-707.
31. Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni MC, Cristini G, Rossi S, et al. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Dig Liver Dis 2001;33:163-172.
32. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, Lujan MS, et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000;7:403-408.
33. Marco VD, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, Di Stefano R, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000;33:456-462.
34. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323.
35. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-793.
36. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, Cremonini C, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-2877.
37. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999;14:2704-2709.
38. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, Pontisso P, et al. A multicenter controlled, randomized, open trial of interferon alpha-2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997;89:3529-3533.
39. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-197.
40. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, Merkel C, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999;46:3216-3222.
41. Chemello L, Cavalletto L, Bernardinello E, Boccato S, Casarin P, Cavinato F, Urban F, et al. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. J Viral Hepat 1999;6:321-327.
42. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89:53-59.
43. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211-215.
44. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 1997;25:754-758.
45. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-205.
46. Horiike N, Fujisawa T, Michitaka K, Tada K, Masumoto T, Iuchi H, Kojima N, et al. The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep 1998;5:1171-1174.
47. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, et al. Long-term interferon therapy for I year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 2001;16:406-415.
48. Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, Kojima J, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. J Epidemiol 2000;10:234-240.
49. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351:1773-1777.
50. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33:1299-1302.
51. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-749.
52. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, et al. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001;61:134-142.
53. Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: Characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000;20:290-295.
54. Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 2000;15 (Suppl):E111-E116.
55. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, Bruneval P, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-2155.
56. Sauleda S, Juarez A, Esteban JI, Altisent C, Ruiz I, Puig L, Esteban R, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040.
57. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, Carbone A, et al. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001;15:1783-1787.
58. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-569.
59. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-872.
60. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-1127.
61. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
62. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.